Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Immix Biopharma, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 7 | 12 | +5 |
| Shares | 183.5K | 299.6K | +116.2K (+63.3%) |
| Value | $475.0K | $406.0K | −$69.0K (−14.5%) |
New holders (5)
Institutions that held Immix Biopharma, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 27,050 | $37.0K | 0.00% |
| Northern Trust Corp | 19,151 | $26.0K | 0.00% |
| FMR LLC | 9 | $0 | 0.00% |
| Morgan Stanley | 3 | $0 | 0.00% |
| Tower Research Capital LLC (TRC) | 250 | $0 | 0.00% |
Sold out (0)
Institutions that held Immix Biopharma, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
None.